

Market Applicability						
Market	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X

## Zyclara (imiquimod)

Override(s)	Approval Duration
Prior Authorization – Age Quantity Limit	56 days of treatment per year

Medications	Quantity Limit
Zyclara 2.5% cream (pump)	1 pump bottle (28 actuations) per 28 days; 56 days of treatment per year
Zyclara 3.75% cream (packets)	14 packets per 28 days; 56 days of treatment per year
Zyclara 3.75% cream (pump) – Brand and generic	1 pump bottle (28 actuations) per 28 days; 56 days of treatment per year

### **APPROVAL CRITERIA**

Requests for Zyclara (imiquimod) may be approved when the following criterion is met:

- I. Individual has had a trial of and inadequate response or intolerance to one preferred topical anogenital wart agent. Preferred agents are as follows: fluorouracil 5% cream, fluorouracil 2% topical solution, fluorouracil 5% topical solution, imiquimod 5% cream packets, podofilox solution.
- II. If Zyclara (imiquimod) packets are requested for individuals with actinic keratosis, 28 packets per 28 days may be approved, if two packets per day are needed to cover the treatment area.
- III. If Zyclara (imiquimod) 3.75% packets are requested for external genital warts, 28 packets per 28 days may be approved.
- IV. If Zyclara (imiquimod) is requested to treat additional actinic keratosis lesions or episodes of external genital warts, an additional course of treatment may be approved.

Requests for Zyclara (imiquimod) for individuals LESS than 12 years of age will be reviewed on a case-by-case basis.

*Note: Zyclara (imiquimod) is NOT indicated for the treatment of common warts (verruca vulgaris).*

*Note: Preferred agents also cover diagnoses of external genital warts (imiquimod 5% cream) along with actinic keratosis (all listed preferred agents)*

CRX-ALL-0595-20

PAGE 1 of 2 09/12/2020

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability						
Market	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X

**Key References:**

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2020. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 9, 2020.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.